RH&P Global Life Sciences Fund A CAP USD

Reference Data

ISIN LU0115986761
Valor Number 1113164
Bloomberg Global ID
Fund Name RH&P Global Life Sciences Fund A CAP USD
Fund Provider RH&PARTNER Investment Funds Basel, Switzerland
Phone: +41 61 378 83 63
E-Mail: info@rh-finanz.ch
Web: https://www.rh-finanz.ch
Fund Provider RH&PARTNER Investment Funds
Representative in Switzerland ACOLIN Fund Services AG
Zürich
Phone: +41 44 396 96 96
Distributor(s) Banque Pictet & Cie SA Credit Suisse
Zürich UBS
n/a Vontobel
n/a
Asset Class Equities
EFC Category Equity Health Care
Distribution Policy Accumulation
Home Country Luxembourg
Issuing Condition The fund management company and/or distributor charges an issuing commission (different commissions can be charged for the same fund depending on the sales channel)
Redemption Condition The fund management company and/or distributor charges a redemption commission (different commissions can be charged for the same fund depending on the sales channel)
Investment Strategy *** N/A
Peculiarities

Fund Prices

Current Price * 169.11 USD 18.11.2024
Previous Price * 170.24 USD 15.11.2024
52 Week High * 188.29 USD 08.11.2024
52 Week Low * 150.21 USD 28.11.2023
NAV * 169.11 USD 18.11.2024
Issue Price *
Redemption Price *
Closing Price *
Indicative Minimum Price
Fund Assets *** 61,638,260
Unit/Share Assets *** 58,436,021
Trading Information SIX

Performance

YTD Performance +0.91% 29.12.2023
18.11.2024
YTD Performance (in CHF) +6.02% 29.12.2023
18.11.2024
1 month -8.20% 18.10.2024
18.11.2024
3 months -9.62% 19.08.2024
18.11.2024
6 months +0.19% 20.05.2024
18.11.2024
1 year +11.65% 20.11.2023
18.11.2024
2 years -1.03% 18.11.2022
18.11.2024
3 years -6.76% 18.11.2021
18.11.2024
5 years +0.52% 18.11.2019
18.11.2024

Tax Data

Equity Participation Rate in %
Share of Total Fund Assets in %
Real Estate Rate in %
ADDI
ADDI Date

Top 10 Holdings ***

Charles River Laboratories International Inc 4.53%
Bio-Techne Corp 4.46%
Nektar Therapeutics 4.36%
Illumina Inc 3.93%
Exelixis Inc 3.87%
Alkermes PLC 3.72%
IQVIA Holdings Inc 3.65%
Biogen Inc 3.59%
Amgen Inc 3.57%
Incyte Corp 3.53%
Last data update 30.04.2021

Cost / Risk

TER *** 2.40%
TER date *** 30.06.2024
Performance Fee ***
PTR
Max. Management Fee *** 1.40%
Ongoing Charges *** 2.29%
SRRI ***
SRRI date *** 31.10.2024

ESG Fund Ratings

Low Carbon Designation ***
ESG Rating Overall ***
ESG Rating Corporate ***
ESG Rating Sovereign ***
% AuM H&S Controversies ***

Breakdowns

Countries ***

Stock Sectors ***

Bond Sectors ***

ESG Carbon Metrics

Avg Carbon Risk Score ***
Avg Carbon Risk Cat Avg ***
% AuM Covered Carbon ***
Avg Fossil Fuel Exposure ***
Fossil Fuel Cat Avg ***

ESG Strategy

Strategy Level 1 ***
Strategy Level 2 ***
Strategy Level 3 ***
Exclusions Level 1 ***
Exclusions Level 2 ***

* NAV / Issue Price exclusive commissions, for listed funds NAV or closing price
** Calculation of interim profit followed § 9 Satz 2 InvStG
*** Data source: Morningstar (Data is based on the rescaled long position of the holdings)